Overview of Урсодез

Property	Description
Active ingredient	Ursodeoxycholic Acid (UDCA)
Form	Hard capsules (for oral use)
Pharmacological class	Hepatoprotector, Cholelitholytic
Common use	Modulation of the bile acid pool
Origin	Secondary bile acid, synthetically derived

What Type of Medicine is Урсодез?

Урсодез is a monocomponent pharmaceutical product defined by its sole active substance, the INN Ursodeoxycholic Acid (UDCA). Pharmacologically, it is classified as a Hepatoprotector, indicating its therapeutic focus on protecting and stabilizing the functional health of the liver, and as a Cholelitholytic agent due to its confirmed ability to dissolve specific types of gallstones. This dual classification establishes the medicine as an intervention within the bile acid group, an approach that is clinically recognized for addressing both the chemical imbalance of bile and the cellular health of the hepatobiliary system. The brand Урсодез is specifically marketed within the Russian Federation for patient groups requiring comprehensive bile acid therapy.

Composition and Form: Ursodeoxycholic Acid Capsules

The formulation of Урсодез is designed for oral administration and is presented as hard capsules. The Ursodeoxycholic Acid contained within is a highly hydrophilic secondary bile acid that is synthetically derived, ensuring pharmaceutical purity. While UDCA exists naturally in the body's bile acid pool, the medication provides a standardized, therapeutic concentration. Presenting the compound within capsules facilitates precise and controlled delivery of the active ingredient through the gastrointestinal tract, which is essential for its absorption and necessary integration into the enterohepatic circulation. This capsule form represents an efficient route for administering bile acid therapy.

General Purpose: Bile Modulation and Protection

The general purpose of the UDCA in Урсодез is to rebalance the overall bile acid pool and protect liver cells. The action is well-supported by pharmacological studies demonstrating that UDCA acts as a Choleretic agent, improving bile flow, and provides a membrane stabilizing effect, which safeguards hepatic cells from harmful cytotoxic bile compounds. This mechanism offers a general benefit by optimizing bile composition and reducing cholesterol saturation, supporting liver and gallbladder function in scenarios where the normal bile acid balance is compromised.

What side effects are possible with Урсодез?

Possible side effects and safety information

Ursodeoxycholic Acid (Урсодез) is characterized by a safety profile that classifies potential reactions by frequency and physiological system, according to official regulatory documents.

Adverse Reaction Classification

Adverse reactions are officially grouped by the system-organ class affected, with the most frequently observed events concerning the gastrointestinal tract:

Gastrointestinal disorders: This class accounts for the most common events documented in regulatory labeling.
Hepatobiliary disorders: Includes very rare, but serious, documented reactions.
Skin and subcutaneous tissue disorders: Contains very rare events such as urticaria.

Frequency Classification	Documented Reactions
Common (affecting 1 to 10 users in 100)	Diarrhoea, pasty stools
Very Rare (affecting less than 1 user in 10,000)	Calcification of gallstones, decompensation of hepatic cirrhosis, severe right upper abdominal pain

Serious Adverse Reactions and Safety Constraints

The medicine's regulatory documents list specific serious adverse reactions and define conditions under which the compound should not be administered. Very Rare events, such as the calcification of existing gallstones and the decompensation of hepatic cirrhosis, have been documented, particularly in patients with advanced liver disease.

Safety is formally constrained by several conditions, including the presence of an acute inflammation of the gallbladder or biliary tract, complete occlusion of the biliary tract, or the presence of radio-opaque calcified gallstones. For women of childbearing potential, regulatory safety measures require the exclusion of pregnancy before initiation of therapy. Furthermore, liver function parameters are officially required to be monitored during the initial phase of treatment exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation provides guidance on potential overdose scenarios for Ursodeoxycholic Acid (Урсодез). The official profile consistently reflects a high safety margin based on clinical experience, noting that there are no documented reports of accidental or intentional overdosage with the substance.

Feature	Official Regulatory Statement
Documented Overdose Presentation	The most likely manifestation of a severe overdose would probably be diarrhea.
Management Focus	Symptomatic treatment is required for the anticipated gastrointestinal effects.
Antidote Status	No specific antidote is known according to official regulatory documentation.

Required Emergency Actions

Immediate contact with emergency services or a Poison Control Center is mandated if an overdose is suspected. Urgent medical help must be sought if a person exhibits severe, life-threatening symptoms, regardless of the cause of exposure.

Immediate Medical Help Required If:

The victim has collapsed.
The victim has had a seizure.
The victim has trouble breathing.
The victim cannot be awakened.

These official statements define a regulatory strategy focused on treating the primary expected symptom while strictly directing users to universal emergency protocols when severe general health concerns are present.

Therapeutic Uses of Урсодез

Урсодез: Main Uses and Benefits

The core substance in this medication is commonly used across conditions presenting with systemic or localized discomfort and those marked by increased physiological stress. This treatment is considered relevant for easing symptoms that interfere with daily functioning and is applied across domains where additional symptomatic support is needed. The active ingredient is commonly used to support these therapeutic areas.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, often used during phases when symptoms become more noticeable. It provides support that helps ease the overall symptom burden and supports patients during episodes of heightened discomfort.

"This treatment is considered relevant for easing symptoms that interfere with daily functioning and is applied across domains where additional symptomatic support is needed."

The medication is commonly used across conditions presenting with acute episodes and those involving episodic or fluctuating manifestations. It may assist with managing symptom clusters that can become intense or disruptive, offering supportive relief when symptoms interfere with routine activities, and supports patients during difficult episodes by easing distress.

Quick Fact: Relief for Noticeable Functional Strain

Eligibility and Restrictions for Use

Official Eligibility Rules for Ursodeoxycholic Acid

The eligibility for using Урсодез (Ursodeoxycholic Acid) is strictly defined by government regulatory documents, focusing on patient population and the functional status of the hepatobiliary system. This section outlines who is allowed, who is restricted, and who is strictly contraindicated from using the medicine.

Contraindicated Populations

Use of this medicine is strictly contraindicated for several patient groups, primarily those with issues related to bile flow or advanced liver disease. Patients must not use Ursodeoxycholic Acid if they have complete obstruction of the biliary tract (e.g., bile duct occlusion), acute inflammation of the gallbladder or bile ducts, or a non-functioning gallbladder. It is also contraindicated for individuals with calcified (radio-opaque) gallstones, frequent episodes of biliary colic, or decompensated hepatic cirrhosis.

Restricted and Age-Related Use

Population Group	Eligibility Status	Regulatory Constraint
Pediatrics	Limited Established Use	Established for children aged 6 years and older for specific approved indications.
Pregnancy	Not Recommended	Use is restricted unless clearly necessary and the potential benefits significantly outweigh the risks.
Lactation	Conditional Use	Not generally recommended due to limited data on excretion into human milk.

Eligibility is generally established for adults. There are no specific restrictions for older adults based solely on age, aligning their use with the standard adult population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ursodeoxycholic Acid (UDCA), the active component in Урсодез, has formally documented interaction patterns primarily involving changes in absorption and altered systemic exposure for co-administered drugs.

Classification Property	Official Regulatory Statement
Interactions resulting in reduced UDCA efficacy	Bile Acid Sequestering Agents (e.g., Cholestyramine, Colestipol) and Aluminum-based Antacids bind UDCA in the intestine, which inhibits its absorption and reduces its effectiveness.
Mandatory Timing Rule	Bile Acid Sequestering Agents and Aluminum-based Antacids must be administered at least two hours before or after Ursodeoxycholic Acid [Source 2.3, 2.4].
Therapeutic Antagonism	Oestrogenic hormones (Estrogens) and Clofibrate increase the secretion of cholesterol into the bile, which directly counteracts the effect of UDCA when used for gallstone dissolution [Source 1.4, 2.3, 2.4].
Exposure Modification	Ursodeoxycholic Acid can increase the intestinal absorption of Ciclosporin, necessitating monitoring of Ciclosporin plasma concentrations. UDCA may also reduce the plasma peak concentrations of agents like Nitrendipine and Dapsone due to pharmacokinetic effects [Source 2.3, 2.4].

The regulatory documentation establishes the interaction structure based on both physical interference, which requires mandatory timing separation, and pharmacokinetic alterations, which require monitoring of co-administered drug levels. The profile also includes the restriction that agents promoting cholesterol gallstone formation should not be combined with UDCA during gallstone dissolution therapy, due to the documented counteracting effect.

Mechanism of Action

The action of Ursodeoxycholic Acid (UDCA) is mediated through three interconnected, peripheral mechanisms focusing on the hepatobiliary system. Firstly, the molecule incorporates itself into the enterohepatic circulation, where it competitively displaces toxic, hydrophobic native bile acids to become the dominant fraction of the bile acid pool. This chemical shift significantly reduces the cholesterol saturation index of the bile fluid, promoting the solubilization and mobilization of cholesterol crystals. Secondly, UDCA confers cytoprotection by integrating into the plasma and mitochondrial membranes of hepatocytes and cholangiocytes. This integration mediates membrane stabilization and inhibits signaling pathways that induce cell death (apoptosis), thereby supporting the structural stability of liver cells and limiting subsequent tissue inflammation. Finally, the mechanism drives a choleretic effect (increased bile flow) by upregulating the activity of key membrane transporters such as the Bile Salt Export Pump (BSEP). This action increases the active secretion of bile components, supporting the egress of biliary fluid through the osmotic gradient created via the AE2 exchanger.

Dosage and Administration Information

Official Instructions for Use

Ursodeoxycholic Acid (UDCA), the active component in Урсодез, is administered via the oral route in the form of hard capsules or tablets. The general principles of its use are governed by two main factors: precise weight-based calculation and the long-term duration of the required course of therapy.

Category	Official Administration Guidelines
Dosing Schedule	Dosage is typically weight-based, utilizing a formula that prescribes milligrams per kilogram of body weight per day. For example, the range for cholelitholytic use is commonly 8 to 10 mg/ kg/ day, while Primary Biliary Cirrhosis (PBC) regimens are 13 to 15 mg/ kg/ day.
Frequency and Timing	The prescribed daily amount is generally given in divided doses to be taken with food, particularly at the start of treatment. Alternatively, the full dose may be consolidated into a single dose administered at bedtime in certain long-term regimens.
Special Administration	Capsules must be swallowed whole with water and should not be crushed or chewed. A specific pediatric dosing guideline exists for children aged 6 to 18 years with Cystic Fibrosis-associated hepatobiliary disorders, set at 20 to 30 mg/ kg/ day.
Course Duration	This medicine is intended for long-term use. Gallstone dissolution therapy may span up to two years, requiring continuation for approximately three months after successful dissolution. Treatment for chronic conditions like PBC is typically continued indefinitely in individuals who respond well.

The standard protocol requires that the medicine be taken consistently over an extended period. The initial use of divided doses ensures optimal distribution before potentially transitioning to a simplified, single nightly dose for maintenance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Урсодез

Evidence for Use in Primary Biliary Cholangitis (PBC)

Ursodeoxycholic Acid (UDCA) was evaluated in many studies related to Primary Biliary Cholangitis (PBC). Research has primarily examined adult patients using long-term Randomized Controlled Trials (RCTs) and extensive observational cohort studies. Studies explored hard clinical endpoints such as overall survival and the need for liver transplantation, as well as biochemical markers (like Alkaline Phosphatase and bilirubin).

Research describes that patterns observed in the studies consistently reported measurements of changes in these markers. However, long-term survival and transplant-free survival findings are inconclusive. The research commonly used changes in biochemical markers as primary study outcomes; certainty remains low regarding the correlation between these markers and long-term clinical well-being.

Evidence for Use in Dissolution of Cholesterol Gallstones

UDCA was evaluated in trials exploring its use as a Cholelitholytic agent. Studies focused on specific populations: patients with small to medium-sized, non-calcified cholesterol gallstones who still retained a functioning gallbladder. Outcomes monitored included the gallstone dissolution rate and measurements of cholesterol saturation in the bile.

Findings describe patterns observed in the studies regarding gallstone dissolution, with evidence suggesting that the outcome was often related to the initial size and composition of the stones. Results apply only to the specific populations studied. Evidence remains limited for other gallstone types (e.g., calcified stones). Follow-up durations were typically limited to six to twelve months, and there is limited information for long-term outcomes, particularly stone recurrence after administration.

Research Gaps and What Remains Uncertain

The structure of the evidence base varies across studies. For Primary Sclerosing Cholangitis (PSC), data show patterns related to biochemical changes, but consistent findings for the critical outcomes of death or liver transplantation are uncertain. Similarly, for Intrahepatic Cholestasis of Pregnancy (ICP), evidence remains limited and findings are mixed regarding a definitive influence on major fetal outcomes. Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain—about the full research landscape.

Key Studies & References

Canadian Agency for Drugs and Technologies in Health (CADTH) Therapeutic Review: Ursodiol (Ursodeoxycholic Acid) for Primary Biliary Cirrhosis

Frequently Asked Questions (FAQ)

Common questions about Урсодез (FAQ)

Q: Can Урсодез be used for gallstones that are not visible on ultrasound?

Official information indicates that this medicine is typically used for radiolucent cholesterol gallstones. Radiolucent means the stones are not calcified (hardened) and do not show up on standard X-ray imaging. Gallstones that are calcified (radio-opaque) are often listed as a contraindication, meaning the drug should not be used, as the medicine is unlikely to be effective in dissolving them.

Q: What should I do if I notice a change in my stool while on Урсодез?

Diarrhoea and pasty stools are commonly reported side effects of the active ingredient, according to regulatory documents. If diarrhoea becomes persistent or severe, official summaries advise that the administration may need to be reduced or discontinued. If changes in side effects are experienced, regulatory guidance suggests consulting a healthcare professional for evaluation.

Q: What is the difference between Урсодез and other brands of ursodeoxycholic acid?

Ursodeoxycholic Acid (UDCA) is the official generic name (INN) of the active substance in the medicine. Урсодез is a specific brand name containing this substance. Regulatory standards require that all approved brands contain the same active ingredient, Ursodeoxycholic Acid.

Q: Does Урсодез affect liver enzyme levels, and how?

Regulatory documents state that abnormal laboratory tests, such as increases in enzymes like AST and ALT, have been reported in some instances. However, the medicine is used in certain liver conditions partly due to its association with decreasing or stabilizing these enzyme levels. Monitoring liver function parameters is a standard part of the treatment protocol described in official documents.

Q: How long does it typically take to see any effects from Урсодез?

For gallstone dissolution, official documents state that the initial response is typically observed after approximately 3 to 6 months of continuous use. The active ingredient concentration usually reaches a steady therapeutic level in the bile fluid in about three weeks.

Q: Is it common to feel tired when starting Урсодез?

Fatigue (tiredness) is listed among the documented side effects in official summaries. Some regulatory documents classify this as a less frequent event in clinical experience.

Q: Can taking Урсодез affect my sleep?

Sleep disorder and general trouble sleeping are listed among the documented adverse reactions in some official product information summaries. This information is included in the official safety profile for reference.

Q: Does Урсодез interact with common vitamins or supplements?

The official drug interaction profile is extensive, and regulatory documents specifically caution that the drug may interact with various vitamins and herbal products. Official guidance suggests informing a healthcare provider about all substances being taken.

Q: Can Урсодез be used by people who have diabetes?

Official warnings state that a potential interaction exists where the active ingredient may increase the action of some oral diabetes medications, such as tolbutamide. This potential interaction is often managed by monitoring under the care of a healthcare professional.

Q: What does the official drug information say about the risk of hair loss with Урсодез?

Hair loss (Alopecia) is officially listed among the documented side effects. Depending on the regulatory source, this effect may be listed in the 1% to 10% frequency range in clinical experience.

Q: Can people with kidney problems use Урсодез?

Official documentation from some regions states that the medicine is contraindicated (should not be used) for patients with existing renal disease (kidney disease). Eligibility is focused on the functional health of the liver and biliary system.

Q: Is it normal to have mild abdominal discomfort when starting Урсодез?

Abdominal discomfort and stomach pain are listed among the documented gastrointestinal adverse reactions in official safety profiles. The regulatory data describes this as a possible experience during treatment.

Q: Are there any contraindications related to specific allergies and Урсодез?

Yes, official documentation lists hypersensitivity to the active ingredient (Ursodeoxycholic Acid) or any other component used in the formulation as a contraindication. Hypersensitivity refers to a known allergic or severe reaction.

Q: What is the guidance on using Урсодез if a person has inflammatory bowel disease?

Some regulatory documents list inflammatory bowel disease (such as Crohn's disease) as a contraindication for the use of the medicine. Contraindications define conditions under which the drug should not be administered.

Q: What does the research say about the effectiveness of Урсодез in non-alcoholic fatty liver disease (NAFLD)?

While the medicine is not officially indicated for this specific use, scientific literature has examined the role of the active ingredient in non-alcoholic fatty liver disease (NAFLD). Evidence and findings described in studies on this topic are often controversial or mixed.

Q: Are there any known interactions between Урсодез and common cold or flu medicines?

The official drug interaction warnings caution against the use of certain medications, including prescription, over-the-counter (OTC) medicines, and vitamins. The official profile lists many potential interactions and advises caution when co-administering any medications.

Q: Are headaches a commonly reported side effect of Урсодез?

Headache is officially listed among the documented adverse reactions in regulatory summaries. Some official sources classify this effect as occurring in over 10% of patients during clinical experience.

Q: Can Урсодез affect mood or cause anxiety?

Regulatory summaries include anxiety and depression among the documented adverse effects. This information is noted in official safety data compiled from clinical experience.

Q: Is Урсодез available without a prescription in any countries?

In the United States, formulations of the active ingredient are typically listed as prescription-only (Rx only). The brand name Урсодез is also typically marketed as a prescription drug, reflecting the need for medical guidance for its use.

Q: What is the official guidance for people with active peptic ulcers regarding Урсодез?

Peptic ulcer has been documented as an adverse effect observed in clinical experience, with some sources listing it in the 1% to 10% frequency range. This information is included in the medicine's official safety profile.

Q: Are there any published studies on combining Урсодез with herbal supplements?

The official drug interaction profiles advise informing a healthcare provider of any herbal products being taken. This caution is included because the medicine has the potential to interact with herbal supplements.

How should Урсодез be stored and disposed of?

Storage Requirements

Official regulatory documents define specific, mandatory conditions for storing Ursodeoxycholic Acid capsules (the active ingredient in Урсодез):

Temperature: Store the medicine at room temperature, typically below 25 C or 30 C, and do not freeze.
Environment: The product must be protected from light and moisture to maintain stability.
Packaging: Keep the capsules in their original container until use, and do not use after the expiry date.
Child Safety: Always keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Урсодез must not be discarded via household waste or flushed down the toilet. Disposal should adhere to local requirements for pharmaceutical waste, and patients should consult a pharmacist for guidance on proper collection points.

Урсодез